Sedation and analgesia in patients who need mechanical ventilation in intensive care unit

Yıl 2018, Cilt: 10 Sayı: 2, 183 - 189, 01.06.2018

Özlem Özkan Kuşcu

https://doi.org/10.21601/ortadogutipdergisi.321197

Öz

Entubated
patients in intensive care unit usually needs medical support to  be in harmony with mechanical ventilation.
Failure to apply proper sedation will result in treatment failure in these
patients. For this reason, intensive care physicians may apply to some agents
to provide sedation and analgesia. The choice of agents is based on many factors
such as the patient's hemodynamics, intracranial pressure, airway dynamics,
drug metabolism. In this review, the most commonly used agents for this purpose
and the reasons why agents are preferred or not will be mentioned.

Anahtar Kelimeler

Critical care, mechanical ventilation, sedation

Yoğun bakımda mekanik ventilasyon uygulanan hastalarda sedasyon ve analjezi

Öz

Yoğun bakımda
entübe takip edilen hastaların mekanik ventilasyona uyum sağlamaları çoğu zaman
medikal destek gerektirir. Uygun sedasyonun uygulanmaması bu hastalarda tedavi
başarısızlığına neden olacaktır.  Bu nedenle
yoğun bakım hekimleri sedasyon ve analjezi sağlamak için bazı ajanlara
başvurabilirler. Ajanların seçimleri hastanın hemodinamisi, kafa içi
basıncı,  havayolu dinamikleri, ilacı
metabolize edebilme durumu gibi birçok durum göz önünde bulundurularak yapılır.
Bu derlemede bu amaçla en sık kullanılan ajanlar ve ajanların tercih edilme ya
da edilmeme nedenlerinden bahsedilecektir.

Anahtar Kelimeler

Yoğun bakım, mekanik ventilasyon, sedasyon

Kaynakça

• KAYNAKLAR 1. Walder, B. and M.R. Tramèr, Analgesia and sedation in critically ill patients. Swiss medical weekly, 2004. 134(23/24): p. 333-346.
• 2. Puntillo, K.A., et al., Symptoms experienced by intensive care unit patients at high risk of dying. Critical care medicine, 2010. 38(11): p. 2155.
• 3. Desbiens, N.A., et al., Pain and satisfaction with pain control in seriously ill hospitalized adults: findings from the SUPPORT research investigations. Critical care medicine, 1996. 24(12): p. 1953-1961.
• 4. Novaes, M., et al., Stressors in ICU: patients’ evaluation. Intensive Care Medicine, 1997. 23(12): p. 1282-1285.
• 5. Ahlers, S.J., et al., Comparison of different pain scoring systems in critically ill patients in a general ICU. Critical Care, 2008. 12(1): p. 1.
• 6. Brook, A.D., et al., Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Critical care medicine, 1999. 27(12): p. 2609-2615.
• 7. Brattebø, G., et al., Effect of a scoring system and protocol for sedation on duration of patients’ need for ventilator support in a surgical intensive care unit. Quality and Safety in Health Care, 2004. 13(3): p. 203-205.
• 8. Bernard De Jonghe, M., et al., Sedation algorithm in critically ill patients without acute brain injury. Crit Care Med, 2005. 33(1): p. 120-27.
• 9. Chanques, G., et al., Impact of systematic evaluation of pain and agitation in an intensive care unit. Critical care medicine, 2006. 34(6): p. 1691-1699.
• 10. Redmond Jr, D. and J. Krystal, Multiple mechanisms of withdrawal from opioid drugs. Annual review of neuroscience, 1984. 7(1): p. 443-478.
• 11. Cox, B., M. Ginsburg, and O. Osman, Acute tolerance to narcotic analgesic drugs in rats. British journal of pharmacology and chemotherapy, 1968. 33(2): p. 245-256. 12. Kissin, I., P.T. Brown, and E. Bradley Jr, Magnitude of acute tolerance to opioids is not related to their potency. Anesthesiology, 1991. 75(5): p. 813-816.
• 13. Tagaito, Y., S. Isono, and T. Nishino, Upper airway reflexes during a combination of propofol and fentanyl anesthesia. The Journal of the American Society of Anesthesiologists, 1998. 88(6): p. 1459-1466.
• 14. Yaster, M., S. Kost-Byerly, and L.G. Maxwell, Opioid agonists and antagonists. Pain in infants, children, and adolescents. Philadelphia: Lippincott Williams and Wilkins, 2003: p. 181-224.
• 15. drugs.com. Morphine. https://www.drugs.com/morphine.html 2016 [cited 2016 24.11.2016].
• 16. Smith, M., Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3‐glucuronide metabolites. Clinical and Experimental Pharmacology and Physiology, 2000. 27(7): p. 524-528.
• 17. Brown, B.R., et al., Narcotic analgesics in anuric patients. The Journal of the American Society of Anesthesiologists, 1975. 42(6): p. 745-747.
• 18. Hanna, M., et al., Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. British journal of anaesthesia, 1990. 64(5): p. 547-550.
• Primary Sources Secondary Sources Uncategorized References 1. Walder, B. and M.R. Tramèr, Analgesia and sedation in critically ill patients. Swiss medical weekly, 2004. 134(23/24): p. 333-346. 2. Puntillo, K.A., et al., Symptoms experienced by intensive care unit patients at high risk of dying. Critical care medicine, 2010. 38(11): p. 2155. 3. Desbiens, N.A., et al., Pain and satisfaction with pain control in seriously ill hospitalized adults: findings from the SUPPORT research investigations. Critical care medicine, 1996. 24(12): p. 1953-1961. 4. Novaes, M., et al., Stressors in ICU: patients’ evaluation. Intensive Care Medicine, 1997. 23(12): p. 1282-1285. 5. Ahlers, S.J., et al., Comparison of different pain scoring systems in critically ill patients in a general ICU. Critical Care, 2008. 12(1): p. 1. 6. Brook, A.D., et al., Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Critical care medicine, 1999. 27(12): p. 2609-2615. 7. Brattebø, G., et al., Effect of a scoring system and protocol for sedation on duration of patients’ need for ventilator support in a surgical intensive care unit. Quality and Safety in Health Care, 2004. 13(3): p. 203-205. 8. Bernard De Jonghe, M., et al., Sedation algorithm in critically ill patients without acute brain injury. Crit Care Med, 2005. 33(1): p. 120-27. 9. Chanques, G., et al., Impact of systematic evaluation of pain and agitation in an intensive care unit. Critical care medicine, 2006. 34(6): p. 1691-1699. 10. Redmond Jr, D. and J. Krystal, Multiple mechanisms of withdrawal from opioid drugs. Annual review of neuroscience, 1984. 7(1): p. 443-478. 11. Cox, B., M. Ginsburg, and O. Osman, Acute tolerance to narcotic analgesic drugs in rats. British journal of pharmacology and chemotherapy, 1968. 33(2): p. 245-256. 12. Kissin, I., P.T. Brown, and E. Bradley Jr, Magnitude of acute tolerance to opioids is not related to their potency. Anesthesiology, 1991. 75(5): p. 813-816. 13. Tagaito, Y., S. Isono, and T. Nishino, Upper airway reflexes during a combination of propofol and fentanyl anesthesia. The Journal of the American Society of Anesthesiologists, 1998. 88(6): p. 1459-1466. 14. Yaster, M., S. Kost-Byerly, and L.G. Maxwell, Opioid agonists and antagonists. Pain in infants, children, and adolescents. Philadelphia: Lippincott Williams and Wilkins, 2003: p. 181-224. 15. drugs.com. Morphine. https://www.drugs.com/morphine.html 2016 [cited 2016 24.11.2016]. 16. Smith, M., Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3‐glucuronide metabolites. Clinical and Experimental Pharmacology and Physiology, 2000. 27(7): p. 524-528. 17. Brown, B.R., et al., Narcotic analgesics in anuric patients. The Journal of the American Society of Anesthesiologists, 1975. 42(6): p. 745-747. 18. Hanna, M., et al., Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. British journal of anaesthesia, 1990. 64(5): p. 547-550. 19. Lindena, G., H. Arnau, and J. Liefhold, Hydromorphon–pharmakologische Eigenschaften und therapeutische Wirksamkeit. Der Schmerz, 1998. 12(3): p. 195-204. 20. Hidromorfonn 2016 17.11.2016; Available from: http://reference.medscape.com/drug/dilaudid-hydromorphone-343313.
• 21. Kuip, E., et al., Pharmacological and clinical aspects of immediate release fentanyl preparations: criteria for selection. European Journal of Hospital Pharmacy: Science and Practice, 2012. 19(1): p. 38-40.
• 22. Feierman, D.E. and J.M. Lasker, Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metabolism and Disposition, 1996. 24(9): p. 932-939.
• 23. Mayes, S., et al., Fentanyl HCl Patient-Controlled Iontophoretic Transdermal System for Pain: Pharmacology The Annals of Pharmacotherapy. 2006.
• 24. Medscape. Fentanyl (Rx). 2016 [cited 2016 17.11.2016]; Available from: http://reference.medscape.com/drug/sublimaze-fentanyl-343311.
• 25. Bovill, J.G., et al., The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. Anesthesiology, 1982. 57(6): p. 439-443.
• 26. Kharasch, E.D. and K.E. Thummel, Human Alfentanil Metabolism by Cytochrome P450 3A3/4. An Explanation for the Interindividual Variability in Alfentanil Clearance? Anesthesia & Analgesia, 1993. 76(5): p. 1033-1039.
• 27. Guignard, B., et al., Acute Opioid ToleranceIntraoperative Remifentanil Increases Postoperative Pain and Morphine Requirement. The Journal of the American Society of Anesthesiologists, 2000. 93(2): p. 409-417.
• 28. drugs.com. remifentanyl. https://www.drugs.com/dosage/remifentanil.html 2016 [cited 2016 25.11.2016].
• 29. Dershwitz, M., et al., Initial clinical experience with remifentanil, a new opioid metabolized by esterases. Anesthesia & Analgesia, 1995. 81(3): p. 619-623.
• 30. Amin, H.M., et al., Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil. Journal of Pharmacology and Experimental Therapeutics, 1995. 274(1): p. 34-39.
• 31. James, M., et al., Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues. Journal of Pharmacology and Experimental Therapeutics, 1991. 259(2): p. 712-718.
• 32. Longnecker, D.E., P.A. Grazis, and G. Eggers Jr, Naloxone for antagonism of morphine-induced respiratory depression. Anesthesia & Analgesia, 1973. 52(3): p. 447-453.
• 33. Flacke, J., W. Flacke, and G. Williams, Acute pulmonary edema following naloxone reversal of high-dose morphine anesthesia. The Journal of the American Society of Anesthesiologists, 1977. 47(4): p. 376-377.
• 34. Drugs.com. Naloxon. https://www.drugs.com/pro/naloxone.html 2016 [cited 2016 25.11.2016].
• 35. Shapiro, B.A., et al., Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. Critical care medicine, 1995. 23(9): p. 1596-1600.
• 36. Glauser, T., et al., Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American epilepsy society. Epilepsy Currents, 2016. 16(1): p. 48-61.
• 37. Sidi, A. and W. Rush, Midazolam's effects on myocardial load and coronary perfusion: Reduced regional O 2 consumption and lactate production during ischemia in dogs. Journal of cardiothoracic and vascular anesthesia, 1994. 8(3): p. 302-309.
• 38. drugs.com. Midazolam. https://www.drugs.com/dosage/midazolam.html 2016 [cited 2016 24.11.2016].
• 39. Greenblatt, D., Sedation: Intravenous benzodiazepines in critical care medicine. The Pharmacologic Approach to the Critically Ill Patient. 3rd ed. Chernow B (Ed). Baltimore, Williams & Wilkins, 1994: p. 321-326. 40. Höjer, J., et al., A placebo‐controlled trial of flumazenil given by continuous infusion in severe benzodiazepine overdosage. Acta anaesthesiologica scandinavica, 1991. 35(7): p. 584-590.
• 41. Medscape. Flumazenile. http://reference.medscape.com/drug/romazicon-flumazenil-343731 2016 [cited 2016 25.11.2016].
• 42. Chambi, D. and S. Omoigui, Precipitation of thiopental by some muscle relaxants. Anesthesia & Analgesia, 1995. 81(5): p. 1112.
• 43. Taniguchi, T., K. Yamamoto, and T. Kobayashi, The precipitate formed by thiopentone and vecuronium. Canadian Journal of Anesthesia/Journal canadien d'anesthésie, 1996. 43(5): p. 511-513.
• 44. Dundee, J.W., W. McCleery, and G. McLOUGHLIN, the hazard of Thiopental Anaesthesia in Porphyria. Anesthesia & Analgesia, 1962. 41(5): p. 567-574.
• 45. Bailie, G., et al., Pharmacokinetics of propofol during and after long term continuous infusion for maintenance of sedation in ICU patients. British journal of anaesthesia, 1992. 68(5): p. 486-491. 46. Langley, M.S. and R.C. Heel, Propofol. Drugs, 1988. 35(4): p. 334-372.
• 47. Mackenzie, S., F. Kapadia, and I. Grant, Propofol infusion for control of status epilepticus. Anaesthesia, 1990. 45(12): p. 1043-1045.
• 48. Brown, L.A. and G.M. Levin, Role of propofol in refractory status epilepticus. Annals of Pharmacotherapy, 1998. 32(10): p. 1053-1059.
• 49. Kelly, D.F., et al., Propofol in the treatment of moderate and severe head injury: a randomized, prospective double-blinded pilot trial. Journal of neurosurgery, 1999. 90(6): p. 1042-1052.
• 50. Foeex, P. and J. Sear, Cardiovascular effects of propofol. JOURNAL OF DRUG DEVELOPMENT, 1991. 4: p. 3-3.
• 51. Bodenham, A., L. Culank, and G. Park, Propofol infusion and green urine. The Lancet, 1987. 330(8561): p. 740.
• 52. Parke, T., et al., Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. Bmj, 1992. 305(6854): p. 613-616.
• 53. Fodale, V. and E. La Monaca, Propofol Infusion Syndrome. Drug safety, 2008. 31(4): p. 293-303.
• 54. Vasile, B., et al., The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive care medicine, 2003. 29(9): p. 1417-1425.
• 55. Ahlen, K., et al., The ‘propofol infusion syndrome’: the facts, their interpretation and implications for patient care. European journal of anaesthesiology, 2006. 23(12): p. 990-998. 56. Bassett, C., Pruritus in a patient with egg hypersensitivity: case report. Reactions, 1994. 504: p. 4.
• 57. Bennett, S.N., et al., Postoperative infections traced to contamination of an intravenous anesthetic, propofol. New England Journal of Medicine, 1995. 333(3): p. 147-154.
• 58. Carrasco, G., et al., Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis. CHEST Journal, 1993. 103(2): p. 557-564. 59. Medscape. Propofol. http://reference.medscape.com/drug/diprivan-propofol-343100#0 2016 [cited 2016 25.11.2016].
• 60. Smith, D.C., et al., A trial of etomidate for rapid sequence intubation in the emergency department. The Journal of emergency medicine, 2000. 18(1): p. 13-16.
• 61. Migden, D.R. and R.F. Reardon, Etomidate sedation for intubation. The American journal of emergency medicine, 1998. 16(1): p. 101-102.
• 62. Van Hamme, M.J., M. Ghoneim, and J.J. Ambre, Pharmacokinetics of etomidate, a new intravenous anesthetic. Anesthesiology, 1978. 49(4): p. 274-277.
• 63. Wagner, R.L. and P.F. White, Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology, 1984. 61(6): p. 647-651.
• 64. Medscape. Etomidat. http://reference.medscape.com/drug/amidate-etomidate-343098#5 2016 [cited 2016 25.11.2016].
• 65. Alhazzani, W., et al., Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Critical care, 2013. 17(2): p. R43.
• 66. Forel, J.-M., et al., Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Critical care medicine, 2006. 34(11): p. 2749-2757.
• 67. Phipps, P. and C. Garrard, The pulmonary physician in critical care• 12: acute severe asthma in the intensive care unit. Thorax, 2003. 58(1): p. 81-88.
• 68. Brunton, L.L., J.S. Lazo, and K.L. Parker, Goodman & Gilman’s the pharmacological basis of therapeutics. 2006, New York: McGraw-Hill. 69. Blosser, S.A. and J.L. Stauffer, Intubation of critically ill patients. Clinics in chest medicine, 1996. 17(3): p. 355-378.
• 70. Orebaugh, S.L., Succinylcholine: adverse effects and alternatives in emergency medicine. The American journal of emergency medicine, 1999. 17(7): p. 715-721.
• 71. Torda, T., et al., Pharmacokinetics and pharmacodynamics of suxamethonium. Anaesthesia and intensive care, 1997. 25(3): p. 272-278.
• 72. Perry, J.J., et al., Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane database syst rev, 2008. 2.
• 73. Naguib, M. and M.M. Magboul, Adverse effects of neuromuscular blockers and their antagonists. Drug safety, 1998. 18(2): p. 99-116.
• 74. Drugs.com. succinylcholine. https://www.drugs.com/monograph/succinylcholine-chloride.html 2016 [cited 2016 24.11.2016].
• 75. Kupfer, Y., et al., Prolonged weakness after long-term infusion of vecuronium bromide. Annals of internal medicine, 1992. 117(6): p. 484-486.
• 76. Drugs.com. Vecuronium. https://www.drugs.com/pro/vecuronium.html 2016 [cited 2016 24.11.2016].
• 77. Magorian, T., K. Flannery, and R.D. Miller, Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients. Anesthesiology, 1993. 79(5): p. 913-918.
• 78. Drugs.com. Rocuronium. https://www.drugs.com/pro/rocuronium-bromide-injection.html 2016 [cited 2016 24.11.2016].
• 79. KHUENL‐BRADY, K., et al., The use of rocuronium (ORG 9426) in patients with chronic renal failure. Anaesthesia, 1993. 48(10): p. 873-875.
• 80. Bom, A., et al., A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin‐based synthetic host. Angewandte Chemie, 2002. 114(2): p. 275-280.
• 81. Drugs.com. Sugammadeks. https://www.drugs.com/ppa/sugammadex.html 2016 (cited 2016).
• 82. Panhuizen, I., et al., Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg− 1 for reversal of deep neuromuscular blockade in patients with severe renal impairment. British journal of anaesthesia, 2015: p. aet586.
• 83. Partownavid, P., et al., Sugammadex: a comprehensive review of the published human science, including renal studies. American journal of therapeutics, 2015. 22(4): p. 298-317.
• 84. Hilgenberg, J., R. Stoelting, and W. Harris, Haemodynamic effects of atracurium during enflurane-nitrous oxide anaesthesia. British journal of anaesthesia, 1983. 55: p. 81S.
• 85. Grigore, A.M., et al., Laudanosine and atracurium concentrations in a patient receiving long-term atracurium infusion. Critical care medicine, 1998. 26(1): p. 180-183.
• 86. Fodale, V. and L. Santamaria, Laudanosine, an atracurium and cisatracurium metabolite. European journal of anaesthesiology, 2002. 19(07): p. 466-473.
• 87. Smith, C., et al., A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R‐cis 1′ R‐cis isomer of atracurium, with atracurium besylate in healthy patients. Anaesthesia, 1997. 52(9): p. 833-841.
• 88. Pramar, Y., V. Loucas, and D. Word, Chemical stability and adsorption of atracurium besylate injections in disposable plastic syringes. Journal of clinical pharmacy and therapeutics, 1996. 21(3): p. 173-175.
• 89. Medscape. Atracurium. http://reference.medscape.com/drug/atracurium-343103#0 2016 [cited 2016 24.11.2016].
• 90. Pignard, J., et al. Physicochemical stability study of injectable solutions of cisatracurium besilate in clinical conditions. in Annales francaises d'anesthesie et de reanimation. 2014.
• 91. Drugs.com. Cisatracurium. https ://www.drugs.com/pro/cisatracurium-besylate-injection.html#bfe12ce5-08e7-4d80-b276-03138f9637e3. 2016 [cited 2016 24.11.2016].
• 92. Medscape. Cisatracurium. 2016 [cited 2016 24.11.2016].